Magnetic resonance imaging volumetric assessment of the extent of contrast enhancement and resection in oligodendroglial tumors: Clinical article

Journal of Neurosurgery

Volumn 116, Issue 6, 2012, Pages 1172-1181

  Sankar, Tejas ^a,b   Moore, Nina Z ^a   Johnson, Joshua ^a   Ashby, Lynn S ^a   Scheck, Adrienne C ^a   Shapiro, William R ^a   Smith, Kris A ^a   Spetzler, Robert F ^a   Preul, Mark C ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Contrast enhancement; Oligodendroglioma; Oncology; Prognosis; Resection; Survival; Volumetric analysis

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER SURGERY; CHROMOSOME 19Q; CHROMOSOME 1P; CONTRAST ENHANCEMENT; FEMALE; GENETIC RISK; HUMAN; HUMAN TISSUE; INTERRATER RELIABILITY; INTRARATER RELIABILITY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; BRAIN; BRAIN DAMAGE, CHRONIC; BRAIN MAPPING; BRAIN NEOPLASMS; CONTRAST MEDIA; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM, RESIDUAL; OLIGODENDROGLIOMA; PROGNOSIS; RETROSPECTIVE STUDIES; SOFTWARE; TUMOR BURDEN; YOUNG ADULT;

EID: 84861996373     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2012.2.JNS102032     Document Type: Article

References (38)

1. Assefa D, Keller H, Ménard C, Laperriere N, Ferrari RJ, Yeung I: Robust texture features for response monitoring of glioblastoma multiforme on T1-weighted and T2-FLAIR MR images: a preliminary investigation in terms of identification and segmentation. Med Phys 37:1722-1736, 2010
2. Brown R, Zlatescu M, Sijben A, Roldan G, Easaw J, Forsyth P, et al: The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 14:2357-2362, 2008
3. Byrne TN: Imaging of gliomas. Semin Oncol 21:162-171, 1994
4. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714, 2006
5. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
6. Celli P, Nofrone I, Palma L, Cantore G, Fortuna A: Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35:1018-1035, 1994
7. Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quiñones-Hinojosa A: Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. Clinical article. J Neurosurg 112:10-17, 2010
8. Chaichana KL, McGirt MJ, Niranjan A, Olivi A, Burger PC, Quinones-Hinojosa A: Prognostic significance of contrastenhancing low-grade gliomas in adults and a review of the literature. Neurol Res 31:931-939, 2009
9. Cohen BA, Knopp EA, Rusinek H, Babb JS, Zagzag D, Gonen O: Assessing global invasion of newly diagnosed glial tumors with whole-brain proton MR spectroscopy. AJNR Am J Neuroradiol 26:2170-2177, 2005
10. Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, et al: Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. J Neurooncol 34:61-78, 1997
11. Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, Mork S, et al: Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 60:248-262, 2001
12. Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF: The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 49:436-440, 1998
13. Harati V, Khayati R, Farzan A: Fully automated tumor segmentation based on improved fuzzy connectedness algorithm in brain MR images. Comput Biol Med 41:483-492, 2011
14. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, et al: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852-9861, 2006
15. Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C: Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129:1884-1891, 2006
16. Keles GE, Lamborn KR, Berger MS: Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 95:735-745, 2001
17. Kros JM, Pieterman H, van Eden CG, Avezaat CJ: Oligodendroglioma: the Rotterdam-Dijkzigt experience. Neurosurgery 34:959-966, 1994
18. Lee YY, Van Tassel P: Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. AJR Am J Roentgenol 152:361-369, 1989
19. Lindegaard KF, Mørk SJ, Eide GE, Halvorsen TB, Hatlevoll R, Solgaard T, et al: Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligodendroglioma. J Neurosurg 67:224-230, 1987
20. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): World Health Organization Classification of Tumours of the Central Nervous System, ed 4. Lyon: IARC, 2007
21. Lwin Z, Gan HK, Mason WP: Low-grade oligodendroglioma: current treatments and future hopes. Expert Rev Anticancer Ther 9:1651-1661, 2009
22. Margain D, Peretti-Viton P, Perez-Castillo AM, Martini P, Salamon G: Oligodendrogliomas. J Neuroradiol 18:153-160, 1991
23. Megyesi JF, Kachur E, Lee DH, Zlatescu MC, Betensky RA, Forsyth PA, et al: Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10:4303-4306, 2004
24. Mikkelsen T, Doyle T, Anderson J, Margolis J, Paleologos N, Gutierrez J, et al: Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol 92:57-63, 2009
25. Mørk SJ, Lindegaard KF, Halvorsen TB, Lehmann EH, Solgaard T, Hatlevoll R, et al: Oligodendroglioma: incidence and biological behavior in a defined population. J Neurosurg 63: 881-889, 1985
26. Ney DE, Lassman AB: Molecular profiling of oligodendrogliomas: impact on prognosis, treatment, and future directions. Curr Oncol Rep 11:62-67, 2009
27. Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, et al: 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 59:126-137, 2004
28. Scerrati M, Roselli R, Iacoangeli M, Pompucci A, Rossi GF: Prognostic factors in low grade (WHO grade II) gliomas of the cerebral hemispheres: the role of surgery. J Neurol Neurosurg Psychiatry 61:291-296, 1996
29. Schiffer D, Dutto A, Cavalla P, Bosone I, Chiò A, Villani R, et al: Prognostic factors in oligodendroglioma. Can J Neurol Sci 24:313-319, 1997
30. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH: Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76:428-434, 1992
31. Shrout PE, Fleiss JL: Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86:420-428, 1979
32. Sled JG, Zijdenbos AP, Evans AC: A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 17:87-97, 1998
33. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645, 2000
34. Sun ZM, Genka S, Shitara N, Akanuma A, Takakura K: Factors possibly influencing the prognosis of oligodendroglioma. Neurosurgery 22:886-891, 1988
35. Talairach J, Tournoux P: Co-planar Stereotaxic Atlas of the Human Brain. Stuttgart: Thieme, 1988
36. van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, et al: MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 27:5881-5886, 2009
37. White ML, Zhang Y, Kirby P, Ryken TC: Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol 26: 784-790, 2005
38. Zagzag D, Goldenberg M, Brem S: Angiogenesis and bloodbrain barrier breakdown modulate CT contrast enhancement: an experimental study in a rabbit brain-tumor model. AJR Am J Roentgenol 153:141-146, 1989